News


  • 05 January 2017

    Atlas Genetics announces positive results from the first US Chlamydia trachomatis beta study

    Atlas Genetics announces positive results from the first US Chlamydia trachomatis beta study

    Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the Point-Of-Care (POC) molecular diagnostics company, today announces positive results from a United States beta study for Chlamydia trachomatis (CT) on its rapid io® diagnostic platform.

  • 05 January 2017

    Marinus Provides Business Outlook for 2017

    Marinus Provides Business Outlook for 2017

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business overview to outline the clinical status of its CNS-selective GABAA modulator, ganaxolone, and an overview of near-term value-creating milestones expected in 2017. 

  • 05 January 2017

    Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent

    Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and  Trademark Office for U.S. Patent Application Number  15/086,485 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”

  • 05 January 2017

    Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

    Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors.

  • 04 January 2017

    Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer

    Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointment of  Richard L. Beckman , M.D. to the position of Chief Medical Officer.

  • 03 January 2017

    Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

    Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).

  • 28 December 2016

    Happy New Year!

    Happy New Year!

    Merry Christmas and a prosperous New Year!  Best wishes for 2017!

    RMI Partners team wishes you Happy Holidays! May all your endeavors and met with huge success and appreciation! Harmony and joy to you and your loved ones!

  • 23 December 2016

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

  • 23 December 2016

    Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

    Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

    Neothetics, Inc.  (NASDAQ:NEOT) today announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of submental subcutaneous fat.

  • 19 December 2016

    The Expert Opinion. Maxim Gorbachev: "2016 Was a Good Year for Our Venture Biotech Portfolio - 2 IPO and 2 Acquisitions"

    The Expert Opinion. Maxim Gorbachev: "2016 Was a Good Year for Our Venture Biotech Portfolio - 2 IPO and 2 Acquisitions"

    Maxim Gorbachev, Managing Partner: "It’s right time to make the first results of 2016. Let’s have a quick look back on venture biotech market in 2016. How 2016 was for RMI Partners? On the contrary, we have a good year. Two of our portfolio companies have made IPO despite unfavorable market conditions and two - have been acquired at pretty nice valuations."